| TIMER2. 0 for analysis of tumor-infiltrating immune cells T Li, J Fu, Z Zeng, D Cohen, J Li, Q Chen, B Li, XS Liu Nucleic acids research 48 (W1), W509-W514, 2020 | 3391 | 2020 |
| Transfer learning enables predictions in network biology CV Theodoris, L Xiao, A Chopra, MD Chaffin, ZR Al Sayed, MC Hill, ... Nature 618 (7965), 616-624, 2023 | 253 | 2023 |
| Natural language processing for EHR-based pharmacovigilance: a structured review Y Luo, WK Thompson, TM Herr, Z Zeng, MA Berendsen, ... Drug safety 40, 1075-1089, 2017 | 183 | 2017 |
| Natural language processing for EHR-based computational phenotyping Z Zeng, Y Deng, X Li, T Naumann, Y Luo IEEE/ACM transactions on computational biology and bioinformatics 16 (1 …, 2018 | 179 | 2018 |
| Therapeutically increasing MHC-I expression potentiates immune checkpoint blockade SS Gu, W Zhang, X Wang, P Jiang, N Traugh, Z Li, C Meyer, B Stewig, ... Cancer discovery 11 (6), 1524-1541, 2021 | 133 | 2021 |
| Statistical and machine learning methods for spatially resolved transcriptomics data analysis Z Zeng, Y Li, Y Li, Y Luo Genome biology 23 (1), 83, 2022 | 114 | 2022 |
| In vivo CRISPR screens identify the E3 ligase Cop1 as a modulator of macrophage infiltration and cancer immunotherapy target X Wang, C Tokheim, SS Gu, B Wang, Q Tang, Y Li, N Traugh, Z Zeng, ... Cell 184 (21), 5357-5374. e22, 2021 | 114 | 2021 |
| Early prediction of acute kidney injury following ICU admission using a multivariate panel of physiological measurements LP Zimmerman, PA Reyfman, ADR Smith, Z Zeng, A Kho, ... BMC medical informatics and decision making 19, 1-12, 2019 | 97 | 2019 |
| Using natural language processing and machine learning to identify breast cancer local recurrence Z Zeng, S Espino, A Roy, X Li, SA Khan, SE Clare, X Jiang, R Neapolitan, ... BMC bioinformatics 19, 65-74, 2018 | 80 | 2018 |
| TISMO: syngeneic mouse tumor database to model tumor immunity and immunotherapy response Z Zeng, CJ Wong, L Yang, N Ouardaoui, D Li, W Zhang, S Gu, Y Zhang, ... Nucleic acids research 50 (D1), D1391-D1397, 2022 | 67 | 2022 |
| Discovering causal interactions using Bayesian network scoring and information gain Z Zeng, X Jiang, R Neapolitan BMC bioinformatics 17, 1-14, 2016 | 64* | 2016 |
| CARM1 inhibition enables immunotherapy of resistant tumors by dual action on tumor cells and T cells S Kumar, Z Zeng, A Bagati, RE Tay, LA Sanz, SR Hartono, Y Ito, ... Cancer discovery 11 (8), 2050-2071, 2021 | 61 | 2021 |
| Tumor aerobic glycolysis confers immune evasion through modulating sensitivity to T cell-mediated bystander killing via TNF-α L Wu, Y Jin, X Zhao, K Tang, Y Zhao, L Tong, X Yu, K Xiong, C Luo, J Zhu, ... Cell Metabolism 35 (9), 1580-1596. e9, 2023 | 55 | 2023 |
| A two-level iteration approach for modeling and analysis of rapid response process with multiple deteriorating patients Z Zeng, Z Fan, X Xie, CH Swartz, P DePriest, J Li Flexible Services and Manufacturing Journal 32, 35-71, 2020 | 40* | 2020 |
| Identifying breast cancer distant recurrences from electronic health records using machine learning Z Zeng, L Yao, A Roy, X Li, S Espino, SE Clare, SA Khan, Y Luo Journal of healthcare informatics research 3, 283-299, 2019 | 38 | 2019 |
| Deep generative classifiers for thoracic disease diagnosis with chest x-ray images C Mao, L Yao, Y Pan, Y Luo, Z Zeng 2018 IEEE International Conference on Bioinformatics and Biomedicine (BIBM …, 2018 | 36 | 2018 |
| Contralateral breast cancer event detection using nature language processing Z Zeng, X Li, S Espino, A Roy, K Kitsch, S Clare, S Khan, Y Luo AMIA Annual Symposium Proceedings 2017, 1885, 2017 | 33* | 2017 |
| Cancer classification and pathway discovery using non-negative matrix factorization Z Zeng, AH Vo, C Mao, SE Clare, SA Khan, Y Luo Journal of biomedical informatics 96, 103247, 2019 | 32 | 2019 |
| Deep learning for cancer type classification and driver gene identification Z Zeng, C Mao, A Vo, L Xiaoyu, JO Nugent, SA Khan, SE Clare, Y Luo BMC bioinformatics, 612762, 2021 | 31* | 2021 |
| Selective progesterone receptor modulators in early-stage breast cancer: a randomized, placebo-controlled phase II window-of-opportunity trial using telapristone acetate O Lee, ME Sullivan, Y Xu, C Rogers, M Muzzio, I Helenowski, A Shidfar, ... Clinical Cancer Research 26 (1), 25-34, 2020 | 28 | 2020 |
Xiaole Shirley LiuCEO, GV20 TherapeuticsVerified email at ds.dfci.harvard.edu
